Navigation Links
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
Date:5/5/2009

(SPA)

SPEAR is an international, multi-center, randomized, controlled, pivotal Phase 3 trial of picoplatin in patients with SCLC who were refractory to or progressed within six months of first-line, platinum-containing chemotherapy. Patients are randomized two to one to receive picoplatin plus BSC verses BSC alone. The initial dose of picoplatin is 150 mg/m squared administered as an intravenous infusion once every three weeks. BSC is designed in accordance with the National Comprehensive Cancer Network's guidelines and includes analgesics, radiation therapy for painful bone metastases, brain metastases or relief of obstructive symptoms from lesions in the chest, nutritional support and treatment of anemia, dyspnea, infections, paraneoplastic syndromes, anxiety or other clinical problems. The primary endpoint of SPEAR is overall survival. Secondary endpoints include overall response rate, progression-free survival, disease control rate and duration of response. The enrollment target for SPEAR was reached and a total of 401 patients were enrolled from over 100 sites worldwide as of March 31, 2009.

The SPEAR study design is agreed to by the U.S. Food and Drug Administration (FDA) under a SPA. Fast Track designation was granted by the FDA and an Orphan Drug designation was granted by the FDA and European Medicines Agency. The study is 90 percent powered to show a 33 percent reduction in risk in overall survival for the treatment arm compared to BSC alone (hazard ratio = 0.67) (p < 0.05). Our Phase 2 study in resistant or refractory disease or patients who relapsed within 180 days of first-line platinum therapy, demonstrated that patients treated with picoplatin showed a median overall survival of 27 weeks(1). Historical data indicates that BSC treatment of patients with recurrent SCLC have a median overall survival of 14 weeks(2). Based on patient enrollment data, the Company believes that overall survival data will be available from t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
2. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
3. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
4. Independent Study Corroborates Pranas Strategy to Treat Alzheimers Disease Patients.
5. Virginia Tech engineers investigate energy independent monitoring system for bridges
6. Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
7. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
8. Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
9. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Genaera,Corporation (Nasdaq: GENR ) today announced the ... Directors, bringing the membership total to,seven. Dr. Wotton is ... term through the Company,s 2009 Annual Meeting., "We ... Board of Directors.,He has a proven record of success ...
... Commercialize ... Novel Technology from UC Davis, BOSTON, June 30 ... university business ventures, has,established RF Biocidics, Inc., to develop and ... The newly formed RF Biocidics, Inc. is developing a ...
... PITTSBURGH, June 30 Cellumen, Inc., the Cellular,Systems ... research,collaboration with the National Center for Toxicology Research ... Administration (FDA). Under the,agreement, Cellumen will use its ... samples of known liver toxicity,compounds including both failed ...
Cached Biology Technology:Genaera Corporation Elects Paul K. Wotton to Board of Directors 2Genaera Corporation Elects Paul K. Wotton to Board of Directors 3Genaera Corporation Elects Paul K. Wotton to Board of Directors 4Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... have recovered fossils from a 60-million-year-old South American snake ... reticulated pythons seem a bit cuter and more cuddly. ... the size of the snake,s vertebrae suggest it weighed ... feet) nose to tail tip -- and that,s a ...
... the visual centers in our brain are humming with activity. ... few years that the magnitude of sense-related activity in a ... to that of one exposed to a stimulus. New research ... explaining why, even though our sense centers are working, we ...
... BETHESDA, Md. (Feb 4, 2009) - Training people to ... in the laboratory helped them to later maintain their ... from the Journal of Neurophysiology . The ... fall prevention strategies that can be generalized to a ...
Cached Biology News:At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 2At 2,500 pounds and 43 feet, prehistoric snake is the largest on record 3Behind closed eyes 2Research model may one day 'inoculate' elderly against slip-related falls 2Research model may one day 'inoculate' elderly against slip-related falls 3
...
... cocktail is tailored to highly ... suspensions of non-human primate (Rhesus ... using the StemSep compatible 0.5 ... The CD4+ T cell content ...
... full microplate washer with a 96 needle wash ... you the best of two worlds high ... ,Separate wash and aspiration channels ensure ... precision of better than 2% CV over the ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: